Merck’s Covid pill is less effective, according to a new analysis

New York, Nov 27, : .

Mercks updated data regarding its molnupiravir tablet against Covid-19 has shown that it is 30% less effective in reducing deaths and hospitalisations than the interim analysisThe interim data released by the US drugmaker October showed that the pill was 50% effective in reducing hospitalisations and deaths among 775 patients.

CNBC reported that Fridays updated rate was based on data from more than 1,400 patients.In addition to a decline in the wider markets, the new data led to a 3% drop in Mercks shares during pre-market trading.An interim analysis of the data showed that 7.3% of patients who received molnupiravir twice daily for five days was hospitalized and that none of them had died within 29 days.This is compared to the 14.1 percent hospitalization rate for placebo patients.The updated data showed that 6.8% of patients receiving molnupiravir were admitted to hospital and one person died.The other placebo group had a hospitalization rate of 9.7%.The UK is currently the only country that has granted a conditional authorization to Mercks Covid Pill.The company stated that the data on the drug Molnupiravir, which was developed with Ridgeback Biotherapeutics had been submitted to US Food and Drug Administration prior to Tuesdays meeting of its expert advisors.

Molnupiravir is currently under review by regulators in Europe as well as other countries.In an effort to help millions of people in developing countries, the company has also agreed that other drugmakers can make its pill.rvt/skp #Covid #pill #effective #analysis.